The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Cyanosis

Cyanosis

Cyanosis is a bluish discoloration of the skin and mucous membranes caused by an abnormal amount of deoxygenated hemoglobin in the blood.
It can indicate a serious underlying condition, such as heart or lung disease, and requires prompt medical attention.
PubCompare.ai's AI-powered tools can help researchers optimize their cyanosis studies by identifying the best reproducible, accurate protocols from the literature, preprints, and patents.
Leverage the platform's data-driven analysis to locate the optimal products and procedures for your cyanosis research, ensuring reiable, data-driven findings.

Most cited protocols related to «Cyanosis»

The study population consisted of greater Worcester residents hospitalized with a discharge diagnosis of AMI at all teaching and community hospitals in the Worcester metropolitan area during the 15 individual study years of 1975 (n=781), 1978 (n=845), 1981 (n=998), 1984 (n=714), 1986 (n=765), 1988 (n=659), 1990 (n=766),1991 (n=848), 1993 (n=953), 1995 (n=949), 1997 (n=1,059), 1999 (n=1,027), 2001 (n=1,239), 2003 (n=1,157), and 2005 (n=903). There were originally 16 hospitals included in this population-based investigation but there are presently 11 due to hospital closures or conversion to chronic care or rehabilitation facilities. Potentially eligible patients were identified through the review of computerized hospital databases of patients with International Classification of Disease discharge diagnoses consistent with the possible presence of AMI (e.g., AMI, unstable angina). The medical records of all potentially eligible patients, who had to be residents of the Worcester metropolitan area since this study is population-based, were reviewed in a standardized manner and the diagnosis of AMI was confirmed according to pre-established criteria that have been previously described (15 (link)-17 (link)).
Cardiogenic shock was defined as a systolic blood pressure of less than 80 mm Hg in the absence of hypovolemia and associated with cyanosis, cold extremities, changes in mental status, persistent oliguria, or congestive heart failure (6 (link),7 (link)). The definition of cardiogenic shock remained the same during all periods studied. This disorder was defined so that patients with classic signs and symptoms of this clinical syndrome would be included.
Publication 2009
Angina, Unstable Closure, Hospital Common Cold Congestive Heart Failure Cyanosis Diagnosis Inpatient Long-Term Care Oliguria Patient Discharge Patients Respiratory Diaphragm Shock, Cardiogenic Syndrome Systolic Pressure
The Institutional Review Board at The Johns Hopkins Hospital approved this prospective, observational cohort study. Because NIRS is routine for pediatric cardiac surgery in our institution, the need for written informed consent was waived. All subjects received routine care, and caregivers were blinded to the COx. Pediatric patients undergoing CPB were eligible with the exception of patients with significant cyanosis (defined as oxygen saturation <95%) or coarctation of the aorta excluded. These latter subjects were excluded based on the theoretical concerns that: (1) patients with aortic coarctation are at risk for markedly abnormal pressure autoregulation associated with chronically high cerebral perfusion pressure; and (2) patients with cyanosis were excluded, because the COx has not been validated in this saturation range.8 (link),9 (link),12 (link) Therefore, of 91 patients identified for the study, 37 were excluded for cyanosis and/or coarctation, leaving 54 subjects enrolled.
All subjects received standard intraoperative monitoring, invasive ABP monitoring, and reflectance NIRS-based cerebral oximetry (INVOS; Somanetics, Troy, Mich). Nonprotocolized anesthetic management consisted of midazolam, fentanyl, isoflurane, and pancuronium. CPB was carried out with a nonocclusive roller pump, α-stat pH management, and priming with blood products for all patients who weighed <20 kg.
Publication 2010
Anesthetics BLOOD Coarctation, Aortic Cyanosis Ethics Committees, Research Fentanyl Homeostasis Isoflurane Midazolam Oximetry Oxygen Saturation Pancuronium Patients Pressure Spectroscopy, Near-Infrared Surgical Procedure, Cardiac

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Age Groups Bronchodilator Agents Child Cough Cyanosis Dentatorubral-Pallidoluysian Atrophy Ethics Committees, Research Haemophilus influenzae type b polysaccharide vaccine Legal Guardians Lethargy Parent Perch Pneumococcal Vaccine Pneumonia Respiratory Rate Seizures Signs and Symptoms, Respiratory Specimen Collection Vaccination Virus Vaccine, Influenza Wall, Chest Wheezing
During an illness visit, pneumonia was diagnosed using WHO criteria and its severity graded [18] . Children with cough or difficulty breathing and a fast respiratory rate, as determined by age specific cut offs (<2 months ≥60 breaths per minute; 2 months –1 year ≥50 breaths per minute and >1 year ≥40 breaths per minute), but no severe signs were diagnosed as having pneumonia. Severe pneumonia was diagnosed in children with cough or difficulty breathing and chest indrawing. Children fulfilling the severe pneumonia criteria but who also had cyanosis or inability to suck were diagnosed with very severe pneumonia.
Pulse oximetry (Hand –held pulse oximeter 512, Respironics), a complete blood count (CBC) (PocH-one 100i, Sysmex), C-reactive protein (CRP) (NycoCard, Axis-Shield), nasopharyngeal aspirate (NPA), and a chest radiograph (CXR) were done on all children with diagnosed pneumonia. NPAs were tested for influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and adenovirus by rRT-PCR [19] .
CXRs were interpreted by two clinicians using the WHO criteria [10] . Results were compared and any conflicting CXRs were examined by a third clinician and the majority diagnosis was used. Where there was no agreement the CXR was deemed uninterpretable.
Pneumonia treatment followed the recommendations in the WHO pocket book of hospital care for children [18] .
Publication 2013
Adenoviruses ARID1A protein, human Chest Child Cough C Reactive Protein Cyanosis Diagnosis Epistropheus Human Metapneumovirus Human respiratory syncytial virus Nasopharynx Orthomyxoviridae Oximetry, Pulse Pneumonia Pulse Rate Radiography, Thoracic Respiratory Rate

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Central Nervous System Child Childbirth Chromosomes Congenital Abnormality Cyanosis Ethics Committees, Research Gestational Age Heart Diseases High-Risk Pregnancy Hospitalization Infant Infant, Newborn Legal Guardians Mechanical Ventilation Oxygen Parent Preterm Infant Reliance resin cement

Most recents protocols related to «Cyanosis»

A hospital-based epidemiological survey was conducted in Guangxi, a province in southern China where HFMD is prevalent. Cases of severe HFMD from 2014 to 2018 were collected from Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control (CDC) system. The definition of severe HFMD was referred to the “diagnosis and treatment guidelines for HFMD” (2010)” [11 ], and the diagnosis criteria are as follow: (1) frequent convulsions, coma and cerebral hernia; (2) breathing difficulties, cyanosis, bloody frothy sputum and pulmonary rales; and (3) shock and circulatory insufficiency. In our study, subjects were included if: (1) Severe HFMD cases: clinical severity was defined as the patient experienced any neurological complications (aseptic meningitis, encephalitis, encephalomyelitis, acute flaccid paralysis, or autonomic nervous system dysregulation) and/or cardiopulmonary complications (pulmonary edema, pulmonary hemorrhage, or cardiorespiratory failure) and/or circulatory system symptoms (pale face, cold limbs, fingers (toes) cyanosis, cold sweat, et al.), Severe HFMD cases were classified if the patients experienced any symptoms belonging to the clinical severity, others were categorized as mild cases [11 , 12 (link)]. (2) Patient’s parents approved of participation; (3) Individuals with completed investigation data. Subjects were excluded if: (1) The neurological dysfunction was caused by non-HFMD; (2) Patients with incomplete investigation data. All participants understood the purpose of the study and signed the informed consent forms. An investigation was performed following the relevant guidelines and regulations; cases of severe HFMD from 2014 to 2018 were collected from Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control (CDC) system, the investigation was done by the staff of the CDC.
The sample size can be calculated by the following formula: n=Z1-α/22π(1-π)δ2 . The annual proportion of severe HFMD diseases was set at about 20% [3 (link), 10 (link)], then we calculated the sample size using the PASS software.
Publication 2023
acute flaccid paralysis Aseptic Meningitis Cardiovascular System Comatose Common Cold Cyanosis Diagnosis Dysautonomia Dyspnea Encephalitis Encephalocele Encephalomyelitis Face Fingers Hemoptysis Hemorrhage Lung Parent Patients Pulmonary Edema Seizures Shock Sweat Systems, Nervous Toes
This retrospective study was approved by the ethical review board of our hospital (IRB number: JD-HG-2021-32). Informed consent was obtained from all patients. Fifty-seven patients with acute arterial embolism in our hospital were enrolled in the study between January 2015 and December 2017, including 45 male and 12 female adults aged from 40 to 88 years, with an average age of 73.52 years. In total, 95 ROIs were detected in these patients, including old emboli (50) and new thromboses (45).
The inclusion criteria were:

a) Clinical manifestations of acute onset, manifested by varying degrees of sudden limb pain, followed by numbness, paleness, cyanosis, dyskinesia, cold limbs, arterial pulse weakening, or disappearance of symptoms;

b) Gross specimen showing that the thrombosis head was sclerotic and the tail thrombosis was soft; pathological diagnosis showing that the head thromboses was white and the tail thromboses was red;

c) Embolus taken immediately after CTA examination of the lower extremities at DSA.

The exclusion criteria included:

a) Artifacts in images;

b) Unclear popliteal artery lumen;

c) Images could not be matched;

d) Nephrotic syndrome.

Figure 2 shows the details of patient selection.
Publication 2023
Adult Arteries Common Cold Cyanosis Diagnosis Dyskinesias Embolism Ethical Review Head Lower Extremity Males Nephrotic Syndrome Pains, Acute Patients Popliteal Artery Pulse Rate Sclerosis Tail Thrombosis Woman
Integrating the above, a list of features was selected for the data collection phase. Considering the results of Round 1 of the Delphi procedure, an approach that compromised between comprehensiveness, veracity, practicality and expected correlation with clinical outcome was chosen. Features of equivalent meaning were combined (accessory muscle use and grunting were combined as respiratory distress for example) or where a quantifiable candidate was available (such as in the case of cyanosis or peripheral oxygen saturation), the quantifiable metric was selected. For level of consciousness, both the AVPU scale (an ordinal score for consciousness—alert, response to verbal stimuli, response to pain, unresponsive) and a broader variable of altered level of consciousness were available (16 (link)). These features represent clinically detectable markers of specific organ dysfunctions. In view of the high prevalence of human immunodeficiency virus (HIV) and malnutrition in South Africa (17 (link)–19 ), the current status of HIV diagnosis and treatment together with anthropometry values were also included for collection as these were thought to be potentially informative features in this clinical setting.
Publication 2023
Consciousness Cyanosis Diagnosis HIV Malnutrition Muscle Tissue Pain Respiratory Rate Saturation of Peripheral Oxygen
All volunteers completed a test of seven signs and symptoms of CMS based on the “Qinghai CMS Score,” which is based on the following symptoms: breathlessness and/or palpitations, sleep disturbance, cyanosis, dilatation of veins, paresthesia, headache, tinnitus, and a final value of 3 if the Hb value is ≥ 21 g/dL.[20 (link)]
Publication 2023
Cyanosis Dyspnea Dyssomnias Headache Paresthesia Tinnitus Varices Voluntary Workers
The study was conducted in Northern Lesotho from 28.12.2020 to 30.09.2021 at the Government District Hospital of Mokhotlong and the St Charles Missionary Hospital Seboche and additionally from 21.01.2021 to 12.02.2021 at the Butha-Buthe Government District Hospital. These hospitals serve a population of about 220’000, mainly living in rural communities scattered over a mountainous area in Northern Lesotho. During the 10 months of the study implementation, the Ministry of Health of Lesotho reported the surge of three waves of increased incidence of COVID-19 cases and implemented social mobility restrictions and lockdowns of different intensity. Lesotho’s first COVID-19 wave started in December 2020, the second in May 2021 and the third in September 2021 [14 ].
As part of routine procedures, all children ≥ 5 years, adolescents, and adults attending health services at one of the hospitals were pre-screened for COVID-19 related symptoms at the entrance gate. Any person with body temperature ≥38°C (non-contact forehead thermometer) or reporting at least one out of the following 10 symptoms was eligible for SARS-CoV-2 testing: fever/chills, cough, tiredness, dyspnea, sore throat, body pain, diarrhea, loss of taste/smell, recent weight loss, night sweats. Further eligible were individuals reporting close contact to a probable or confirmed COVID-19 case in the last 14 days, defined as contact <1m for ≥15 min, direct physical contact, or direct care without appropriate personal protective equipment.
Informed consent was obtained after pre-screening. A focused medical history was obtained, and a clinical examination was performed on each subject enrolled in the study. Individuals who were deemed critically ill by the healthcare provider, i.e., adults with altered mental status, tachypnea (≥22/min), SpO2<94%, or systolic blood pressure <100mgHg, and children with signs of pneumonia and central cyanosis, SpO2<94%, general danger signs, or tachypnea (5–9 yrs ≥ 30/min, ≥10 yrs ≥ 20/min) were assessed by a hospital physician, who decided whether the participant could remain in the study for all investigations or immediately referred to emergency care.
Publication 2023
Adolescent Ageusia Body Temperature Child Chills Cough COVID 19 Critical Illness Cyanosis Diarrhea Dyspnea Fatigue Fever Forehead Health Personnel Human Body Missionaries Pain Physical Examination Physicians Pneumonia Respiratory Diaphragm Rural Communities SARS-CoV-2 Saturation of Peripheral Oxygen Sense of Smell Service, Emergency Medical Social Mobility Sore Throat Sweat Systolic Pressure Taste Thermometers

Top products related to «Cyanosis»

Sourced in United States, Germany, Japan, Italy, Canada, United Kingdom, Sweden, Sao Tome and Principe, Macao, China
Avertin is a laboratory reagent used as an anesthetic agent in various animal studies and experiments. It is a combination of 2,2,2-tribromoethanol and tert-amyl alcohol. Avertin induces a state of general anesthesia in animals, allowing for safe and controlled procedures to be performed.
Sourced in United States
The VentElite 55-7040 is a ventilator system designed for laboratory research. It provides controlled ventilation to small animals during experiments. The device features adjustable tidal volume, breathing rate, and inspiratory/expiratory ratio to accommodate various research requirements.
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, Japan, Italy, Canada, Hungary, Macao
Pentobarbital sodium is a laboratory chemical compound. It is a barbiturate drug that acts as a central nervous system depressant. Pentobarbital sodium is commonly used in research and scientific applications.
Sourced in Italy
The Pony FX is a compact, high-performance laboratory centrifuge designed for a variety of applications. It features a brushless motor and can achieve speeds of up to 6,000 RPM, making it suitable for a range of sample separation tasks. The Pony FX is a versatile and reliable piece of equipment for use in clinical, research, and educational settings.
Sourced in United States
The Model 683 is a syringe pump that is designed for precise fluid delivery in laboratory applications. It features a microprocessor-controlled stepper motor drive and can accommodate a wide range of syringe sizes. The pump can deliver flow rates from 0.001 μL/hr to 220.8 mL/min, with an accuracy of ±0.5%.
Sourced in Italy
The Quark C12x is a calorimetry device designed for indirect calorimetry measurements. It utilizes gas analysis to determine the respiratory exchange ratio and energy expenditure.
Sourced in United States
The Nellcor™ Bedside SpO2 Patient Monitoring System is a device designed to measure and monitor a patient's oxygen saturation levels in the blood. It utilizes pulse oximetry technology to provide continuous, noninvasive monitoring of the patient's oxygen saturation.
Sourced in Japan
The UA-767 Plus is a compact, digital blood pressure monitor designed for clinical use. It features an oscillometric measurement method and is capable of measuring blood pressure and pulse rate. The device is powered by batteries and includes a LCD display to show the measured values.
Sourced in Germany, United Kingdom
Fentanyl is a synthetic opioid analgesic used in laboratory settings for research purposes. It is a powerful pain-relieving substance that is typically used in controlled medical environments. The core function of Fentanyl is to serve as a research tool for scientific investigations, but its detailed applications should be discussed with qualified professionals.

More about "Cyanosis"

Cyanosis is a condition characterized by a bluish discoloration of the skin and mucous membranes, caused by an abnormal amount of deoxygenated hemoglobin in the blood.
This can be an indicator of a serious underlying medical issue, such as heart or lung disease, and requires prompt medical attention.
Researchers studying cyanosis can leverage PubCompare.ai's AI-powered tools to optimize their research protocols.
The platform's data-driven analysis can help identify the best reproducible and accurate protocols from the literature, preprints, and patents.
This can ensure reliable and data-driven findings.
Some key subtopics and related terms to consider in cyanosis research include: Deoxygenated hemoglobin, Anoxia, Hypoxia, Dyspnea, Respiratory distress, Cardiovascular disease, Pulmonary disease, Avertin (a barbiturate anesthetic), VentElite 55-7040 (a ventilator), Pentobarbital sodium (a sedative), Pony FX (a vital signs monitor), Model 683 (a pulse oximeter), Quark C12x (a cardiac output monitor), NellcorTM Bedside SpO2 Patient Monitoring System (a pulse oximeter), UA‐767 Plus (a blood pressure monitor), and Fentanyl (a potent opioid analgesic).
Leveraging these tools and technologies can enhance the quality and reliability of cyanosis research.